NIH programs shed light on gene variants and their connections to health and disease

October 12, 2018, NIH/National Human Genome Research Institute

Programs supported by the National Institutes of Health are establishing which genes and genomic variants play a role in human disease, enabling their use in genomic medicine and research. NIH's Clinical Genome Resource (ClinGen) and ClinVar programs address a major barrier to incorporating genomic medicine into healthcare, which is a lack of evidence about the relationship between gene variants and diseases. A special issue of Human Mutation, published on Oct. 12, highlights the broad array of advances made through these programs, which work in concert to advance knowledge connecting human genomic variation to human health. 

The National Human Genome Research Institute (NHGRI) established ClinGen in 2013 with additional support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute. The goal of ClinGen is to bring together clinical and research experts to develop standard processes for reviewing data about gene variants and their connections to health and disease. These experts then determine what each might mean for disease diagnosis and treatment. Information on the gene variants is stored in ClinVar, which is funded and maintained by NIH's National Center for Biotechnology Information, part of the National Library of Medicine. 

"Through the work of ClinGen and ClinVar, more than 730 researchers, clinicians and curators from 230 institutions have been working together to standardize the evaluation of genes and genomic variants implicated in human disease," said Eric Green, M.D., Ph.D., NHGRI director.  "Ultimately, these efforts will lead to improved implementation of and higher-quality patient care." 

Providing evidence

ClinGen researchers developed a Gene-Disease Validity Framework to evaluate the role of gene variants in a given disease. Fourteen gene curation expert panels, comprised of clinicians and researchers from around the world with expertise in diseases such as cancer, neurodevelopmental disorders and cardiovascular disease, are implementing this framework. In the special issue, two expert panels reported on genes associated with epilepsy and RASopathies; the latter is a group of rare genetic conditions that include Noonan syndrome, Cardio-Facio-Cutaneous syndrome, Costello syndrome and Legius syndrome. Eight of 16 genes for epilepsy along with six of the 20 genes evaluated for their contribution to RASopathies had insufficient evidence to support a role in disease. These findings will help guide laboratories to decide which genes to test as part of diagnostic evaluations.  

ClinGen researchers are also leveraging guidelines developed by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology to identify those specific variants within a gene that lead to disease and those that do not. In four published papers, ClinGen's Variant Curation Expert Panels provide an overview of how they customized the guidelines to address unique aspects of the , including those for hearing loss, CDH1 (associated with stomach and breast cancer), PAH (associated with phenylketonuria), and PTEN (associated with a tumor syndrome). Clinicians can use the expert-classified gene variants available in ClinVar to decide whether a variant they encounter in their patients is contributing to disease. Researchers can also select certain gene variants to study in their laboratories. 

"ClinGen and ClinVar are great examples of how different parts of NIH, the extramural research community and clinical testing laboratories from around the world have joined forces to improve how we share genomic information and use it to improve our understanding of the relationship between variation in DNA sequence and disease," said Heidi L. Rehm, Ph.D., a clinical genomicist and a ClinGen principal investigator at the Broad Institute of MIT and Harvard and Massachusetts General Hospital, Boston. Dr. Rehm, Jonathan S. Berg, M.D., Ph.D., University of North Carolina at Chapel Hill; and Sharon Plon, M.D., Ph.D., Baylor College of Medicine, Houston, provided an overview of the programs and served as co-editors for the 25-paper special issue. 

ClinGen researchers have also developed an approach to assess the clinical actionability of secondary findings, which in this context are genomic variants identified in a person that could potentially cause a disease even if they were not the original focus of the diagnostic test. 

Data sharing

The ClinVar database aggregates information about genomic variants and their relationship to human health and has fostered the ability to share and compare classifications from different research and clinical groups. This has been critical to the work of ClinGen's expert panels by allowing them to work closely with the laboratories sharing data to resolve differences in gene variant interpretations, ensuring more accurate results for patients.  

ClinGen's patient registry, GenomeConnect, has enabled patients who have undergone genomic testing to contribute their genomic variants and clinical data to ClinVar. As of April 2018, 1,601 participants from 32 countries had enrolled in GenomeConnect. The registry also enables patients to connect with clinicians, researchers and other participants. Registry participants can also be alerted when the laboratory that performed their testing updates information about their gene variants. To date, 13 updates have been identified and are being returned to participants who choose to receive this information. 

A common language

To help establish a common language for genomic databases to "speak" to each other, ClinGen developers built the ClinGen Allele Registry, which enables universal identification of gene variants. The data model underlying the registry conforms to the standards being developed by the Genomic Knowledge Standards Work Stream of the Global Alliance for Genomics and Health. "ClinGen and ClinVar researchers and clinicians have worked tirelessly to curate knowledge for use in genomic medicine and research," said Erin M. Ramos, Ph.D., M.P.H., and NHGRI's ClinGen Program Director. "It's an enormous challenge, but the community is working to automate approaches and speed up our processes. Given that clinical genomic testing is becoming more common, knowing which gene variants contribute to disease is imperative to providing the best care possible."

Explore further: ClinGen Panel evaluates validity of genes reported to be associated with Brugada Syndrome

More information: Alice B. Popejoy et al, The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics, Human Mutation (2018). DOI: 10.1002/humu.23644

Related Stories

ClinGen Panel evaluates validity of genes reported to be associated with Brugada Syndrome

June 29, 2018
Clinical laboratories often rely on medical articles and public information on gene disease associations in determining the genes to include on genetic testing panels for specific conditions or the specific results to return ...

A new era for genetic interpretation

May 27, 2015
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in ...

Researchers develop novel system for cataloging cancer gene variants

November 16, 2016
The discovery of variations in genes in tumor samples has been critical to the understanding of how cancer develops and spreads, and how to effectively treat it. Now, a multi-institutional group of researchers from the National ...

A new era in the interpretation of human genomic variation

July 17, 2017
In a commentary published today in Genetics in Medicine, Heidi Rehm, PhD, highlights the pressing need for standardized human genomic variant interpretation and calls on more stakeholders to join the data sharing movement.

Expert: Keep up with latest discoveries through automated updates in reporting genetic test results

October 1, 2018
Maybe the genetic test report your doctor ordered says your DNA contains many "variants of unknown significance." Currently, up to 70 percent of such reports are negative or inconclusive. But suppose at a later date a researcher ...

NIH pilot project will match researchers to genes, gene variants of interest

March 1, 2018
Databases such as the 1000 Genomes Project and the Exome Aggregation Consortium (ExAC) harbor large numbers of genotypes (an individual's collection of genes). Until now, it has been difficult for researchers to re-contact ...

Recommended for you

Hair colour gene study sheds new light on roots of redheads' locks

December 10, 2018
Scientists have discovered eight genes linked to red hair, helping to solve a mystery of how redheads inherit their flaming locks.

Big datasets pinpoint new regions to explore the genome for disease

December 10, 2018
Imagine rain falling on a square of sidewalk. While the raindrops appear to land randomly, over time a patch of sidewalk somehow remains dry. The emerging pattern suggests something special about this region. This analogy ...

Genetic changes associated with physical activity reported

December 10, 2018
Time spent sitting, sleeping and moving is determined in part by our genes, University of Oxford researchers have shown. In one of the most detailed projects of its kind, the scientists studied the activity of 91,105 UK Biobank ...

Team seeks to create genetic map of worm's nervous system

December 10, 2018
How do you build a brain? What "rules" govern where neurons end up, how they connect to each other, and which functions they perform?

Genetic study of epilepsy points to potential new therapies

December 10, 2018
The largest study of its kind, led by international researchers including scientists at RCSI (Royal College of Surgeons in Ireland), has discovered 11 new genes associated with epilepsy.

Scientists cut main heart disease risk locus out of DNA by genome editing

December 6, 2018
Over the past decade we've learned that billions of people carry a mysterious specter in their DNA that strongly increases their risk for life threatening cardiovascular diseases, such as heart attacks, aneurysms or strokes, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.